Chemokine redundancy versus specificity in the context of CXCR3 and its ligands

Autor: Amanda JL Ridley, Douglas P Dyer

Publikováno v: Ridley, A J & Dyer, D P 2022, ' Chemokine redundancy versus specificity in the context of CXCR3 and its ligands ', Immunology and cell biology, vol. 100, no. 6, pp. 387-389 . https://doi.org/10.1111/imcb.12553

In a recent article published in Immunology & Cell Biology, Dalit et al. describe how correcting mutations in the C57BL/6 mouse strain can restore production of the chemokine CXCL11, although surprisingly, this expression of CXCL11 had little effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bb8e941462967503928d771b99bf490
https://www.research.manchester.ac.uk/portal/en/publications/chemokine-redundancy-versus-specificity-in-the-context-of-cxcr3-and-its-ligands(759ad280-b58d-4bff-bbae-37d90aee3f28).html

Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians

Autor: Thi H. O. Nguyen, Jane Davies, Aeron C. Hurt, Carolien E van de Sandt, Malet Aban, Damian A. Oyong, Marios Koutsakos, Kim L. Harland, Steven Y. C. Tong, Jessica R. Webb, Katie L. Flanagan, Cath Blacker, Adam K. Wheatley, Peter C. Doherty, Jane Nelson, Louise C. Rowntree, Amy W. Chung, Timon Damelang, Anngie Everitt, Katherine Kedzierska, Maria Auladell, E. Bridie Clemens, Stephen J. Kent, Luca Hensen, Magdalena Plebanski, Bruce D. Wines, Jessica R. Loughland, P. Mark Hogarth, Adrian Miller

Publikováno v: Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, 118(41). National Academy of Sciences

Significance Indigenous populations worldwide are highly susceptible to influenza virus infections. Vaccination with inactivated virus is highly recommended to protect Indigenous populations, including Indigenous Australians. There is no study to dat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8177d032c766c8c1ba09d40bd774890
https://doi.org/10.1073/pnas.2109388118

Serum cytokine patterns in immunoglobulin m monoclonal gammopathy-associated polyneuropathy

Autor: Elisabeth A. Cats, W-Ludo van der Pol, Abraham C. J. Stork, Nicolette C. Notermans, Jan H. Veldink, Ruth D E Fritsch-Stork, Ben A.W. de Jong, Lotte Vlam, Ger T. Rijkers, Leonard H. van den Berg

Publikováno v: Muscle & Nerve, 59(6), 694-698. John Wiley & Sons Inc.
Muscle & Nerve, 59(6), 694. John Wiley and Sons Inc.

Introduction Polyneuropathy with immunoglobulin M monoclonal gammopathy (IgM-PNP) is associated with the presence of IgM antibodies against nerve constituents such as myelin associated glycoprotein (MAG) and gangliosides. Methods To test whether B-ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b6d006ccacc99a46ca4739a62651fbb
https://doi.org/10.1002/mus.26462

Single-cell transcriptome profiling and the use of AID deficient mice reveal that B cell activation combined with antibody class switch recombination and somatic hypermutation do not benefit the control of experimental trypanosomosis

Autor: Magdalena Radwanska, Stefan Magez, Hang Thi Thu Nguyen, Robin B. Guevarra

Publikováno v: PLoS Pathogens
PLOS PATHOGENS
PLoS Pathogens, Vol 17, Iss 11, p e1010026 (2021)

Salivarian trypanosomes are extracellular protozoan parasites causing infections in a wide range of mammalian hosts, with Trypanosoma evansi having the widest geographic distribution, reaching territories far outside Africa and occasionally even Euro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c47e3f7f7cb5d23162e5d5c18750af98
https://pubmed.ncbi.nlm.nih.gov/34762705

Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

Autor: Lars Fugger, Ralf Gold, Kate Attfield, Astrid K. N. Iversen, Hannah Wurm, Aiden Haghikia

Publikováno v: Attfield, K, Iversen, A K, Gold, R, Fugger, L & Haghikia, A 2020, ' Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient ', Multiple sclerosis (Houndmills, Basingstoke, England), vol. 26, no. 10, pp. 1261-1264 . https://doi.org/10.1177/1352458520943791
Multiple Sclerosis (Houndmills, Basingstoke, England)

Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93d12eb597e93dc5973e5a82e0a59c11
https://ora.ox.ac.uk/objects/uuid:1394a7bc-38fc-4e9a-b856-10f5a22a4f2a